Warning against the use of static preservation solution due to potential contamination with bacteria

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: On Dec. 14, 2016, staff at a health care facility notified the FDA of an uncharacteristic odor from SPS-1 encountered during an organ procurement operation. Laboratory results from fluid samples and cultures from the SPS-1 used for this operation confirmed contamination with Pantoea and Enterococcus (intrinsically vancomycin-resistant) bacteria.

While it is not yet known how the SPS-1 used for this operation became contaminated, Organ Recovery Systems immediately initiated a voluntary removal of two lots of SPS-1: Lot Numbers PBR-0060-392 and PBR-0074-330.

On Jan. 12, 2017, Organ Recovery Systems notified customers of another report of an uncharacteristic odor from SPS-1 from a different lot, Lot Number PBR-0074-337, suggestive of potential contamination. Additionally, SPS-1 from Lot Number PBR-0060-386 was reported as being present when an odor was noticed, although the report did not identify any odor coming directly from this product.

Since then, Organ Recovery Systems temporarily suspended production and distribution of all SPS-1 products, and added Lot Numbers PBR-0074-337 and PBR-0060-386 to their recall.

On March 8, 2017, Organ Recovery Systems updated customers on the voluntary removal of SPS-1 and stated that additional sterility testing of randomly selected bags of SPS-1 should be completed by March 31, 2017.

To date, there have been no reports to the FDA of any post-operative infections or other adverse events directly linked to the identified products.

BACKGROUND: SPS-1 Static Preservation Solution (SPS-1), manufactured by Organ Recovery Systems, Inc., is a clear to light yellow, sterile solution intended for the flushing and cold storage of kidney, liver, and pancreas at the time of organ removal from the donor in preparation for storage, transportation, and eventual transplantation into a recipient.

The FDA is working with the Centers for Disease Control and Prevention (CDC), the Health Resources and Services Administration (HRSA), and state public health departments to actively investigate the potential for contamination in Organ Recovery Systems’ SPS-1.

 

RECOMMENDATION: In addition to following the standard precautions, the FDA recommends facilities and staff:

  • Be aware that Organ Re...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert - Absorb GT1 Bioresorbable Vascular Scaffold associated with increased risk of CV events

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Safety Alert: breast implants associated with risk of developing anaplastic large cell lymphoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Odactra for house dust mite allergies

Read more
  • FDA Drug Updates
  • no comment

Approval of Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of SynchroMed Implantable Infusion Pump by Medtronic due to hindered drug delivery during priming bolus procedure

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Siliq (brodalumab) for psoriasis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Parsabiv (etelcalcetide) for hyperparathyroidism in dialysis patients

Read more
  • FDA Drug Updates
  • 1 comment

FDA approval of Emflaza (deflazacort) for duchenne muscular dystrophy

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of herbal and dietary supplements by Regeneca – Not manufactured in compliance with GMPs

Read more
  • MedWatch Drug Updates
  • 1 comment

Warning against the use of static preservation solution due to potential contamination with bacteria

Read more
  • MedWatch Drug Updates
  • 1 comment

Safety alert against use of balloon angioplasty devices to treat autonomic dysfunction

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Trulance (plecanatide) for chronic idiopathic constipation

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Edex (alprostadil injection) 10 mcg by Endo Pharmaceuticals - Lack of sterility assurance

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of unexpired sterile injectable labelled “Latex Free” by Advanced Pharma as it may contain synthetic/natural latex

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of XtraHRD Natural Male Enhancement Capsules by Organic Herbal Supply - Contains undeclared drug ingredients

Read more
  • FDA Drug Updates
  • 1 comment

First drug approved for treatment of spinal muscular atrophy

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rubraca (rucaparib) for BRCA+ advanced ovarian cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Eucrisa (crisaborole) for atopic dermatitis

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Human chorionic gonadotropin freeze dried vials by Synergy Rx – Lack of sterility assurance

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Tecentriq (atezolizumab) for treatment of urothelial carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xultophy 100/3.6 (insulin degludec and liraglutide injection)

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Soliqua 100/33 (insulin glargine and lixisenatide) for type II diabetes

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Dialog+ Hemodialysis System by B. Braun Medical due to defective conductivity sensors

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Alaris Syringe Pump Module by CareFusion – Faulty sensor may generate false alarm

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Ibuprofen lysine injection, 20 mg /2 mL by Exela Pharma Sciences – Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Well Balance Xanthium & Siler Combo dietary supplement by Kingsway - Contains banned ephedra alkaloids

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nuplazid (pimavanserin) for Parkinson’s disease psychosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of FindrWIRZ Guidewire System by SentreHeart – Possible separation of polytetrafluoroethylene coating

Read more